WO2025238661 - AN IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB
National phase entry is expected:
Publication Number
WO/2025/238661
Publication Date
20.11.2025
International Application No.
PCT/IN2025/050758
International Filing Date
15.05.2025
Title **
[English]
AN IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB
[French]
PROCÉDÉ AMÉLIORÉ POUR LA PRÉPARATION D'OSIMERTINIB
Applicants **
BDR LIFESCIENCES PRIVATE LIMITED
Inventors
SHAH, Dharmesh Mahendrabhai
PARAMESHWARAPPA, Gangajji
KOKKIRALA, Tej Kumar
SANGITA, .
SHAH, Hardikkumar Hasmukhlal
BAJANIYA, Sanjay Jayantilal
PATEL, Vijaykumar Dinubhai
Priority Data
202421038864
17.05.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1955 | |
| EPO | Filing, Examination, Granting | 11611 | |
| Japan | Filing, Examination, Granting | 1890 | |
| South Korea | Filing, Examination, Granting | 1528 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,724
Contact Us
Abstract[English]
The present invention relates to an improved process for the preparation of Osimertinib of Formula I or a pharmaceutically acceptable salt thereof. Formula I The present invention also relates to an improved process to obtain Osimertinib of formula (I) or pharmaceutically acceptable salt thereof, essentially free of process byproducts or contaminants.[French]
La présente invention concerne un procédé amélioré pour la préparation d'osimertinib de formule I ou d'un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne également un procédé amélioré pour obtenir de l'osimertinib de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, essentiellement exempt de sous-produits ou de contaminants de processus.